Sign up for Englemed updates from TwitterSign up for Englemed updates from Facebook
Contact Englemed
Our contact email address.
We can provide a specialist, tailored health and medical news service for your site.
Click here for more information
RSS graphic XML Graphic Add to Google
About Englemed news services - services and policies.
Englemed News Blog - Ten years and counting.
Diary of a reluctant allergy sufferer - How the British National Health Service deals with allergy.
BookshopFor books on women's health, healthy eating ideas, mental health issues, diabetes, etc click here

WWW Englemed
Copyright Notice. All reports, text and layout copyright Englemed Ltd, 52 Perry Avenue, Birmingham UK B42 2NE. Co Registered in England No 7053778 Some photos copyright Englemed Ltd, others may be used with permission of copyright owners.
Disclaimer: Englemed is a news service and does not provide health advice. Advice should be taken from a medical professional or appropriate health professional about any course of treatment or therapy.
Metformin could be a treatment for women with pre-eclampsia
Thurs September 23rd - Metformin shows promise as a treatment for preterm pre-eclampsia, a study reveals today. More
AI identifies possible drug combination for brain cancer
Thurs September 23rd - Artificial intelligence-enhanced tools have been used to identify a new combination of drugs that could treat a rare and incurable childhood brain cancer. More
On 09/10/2020 William Haworth wrote:
How long is recovery time after proceedure... on Ablation cuts atrial fibrillat...
On 08/02/2018 David Kelly wrote:
Would you like to write a piece about this to be i... on Researchers unveil new pain re...
On 23/10/2017 Cristina Pereira wrote: on HIV breakthrough - MRC...
On 12/09/2017 Aparna srikantam wrote:
Brilliant finding! indeed a break through in under... on Leprosy research breakthrough...
On 01/07/2017 Annetta wrote:
I have been diagnosed with COPD for over 12 years.... on Seaweed plan for antimicrobial...

Pathway discovered for bowel cancer drug failure

Tuesday September 14th 2021

A protein pathway prevents some bowel cancer drugs from working, researchers reported last night.

Researchers behind the study, which was published yesterday in the Proceedings of the National Academy of Sciences, say they hope finding the pathway, which involves a tetraspanin protein, will lead to an increase the number of bowel cancer patients who can be successfully treated.

The research, led by the University of Birmingham, studied 184 tumour samples and medical records of bowel cancer patients participating in the COIN trial, and involved research carried out in mice, cell cultures, and a laboratory model for pre-malignant colorectal cancer.

Co-senior author Dr Fedor Berditchevski, of the University of Birmingham, said: “Scientists have previously found that if bowel cancer patients have a mutation in a gene called RAS, the anti-EGFR inhibitors will not work.

“However, our research has now discovered a new pathway involving a tetraspanin protein called TSPAN6 that is frequently inactive in bowel cancer patients and this makes these drugs less effective.

“Crucially, our research also shows that if this pathway is active in a patient’s cancer, then the drug will work, irrespective of whether they have a mutation in RAS or not.”

First author Dr Regina Andrijes, a postdoctoral Fellow at the University of Birmingham, who worked with colleagues at University Hospitals Birmingham NHS Foundation Trust, Semmelweis University in Hungary, and Assiut University in Egypt, said it is the first time a tetraspanin protein has been shown to be directly involved with bowel cancer.

“Our research findings show that this new pathway could act as a biomarker for treatment with anti-EGFR drugs in bowel cancer, increasing a patient’s chance of survival and the number of patients who could benefit from these drugs who previously would not have,” she added.

A clinical trial to use this marker to better identify patients for anti-EGFR treatment is being planned.

Andrijes et al. Tetraspanin 6 (Tspan6) is a new regulator of carcinogenesis in colorectal cancer. PNAS 13 September 2021.

[COIN trial]

Tags: Cancer | Gastroenterology | Pharmaceuticals | UK News

Printer friendly page Printer friendly page

Comment on this article:

<a>,<b> & <p> tags allowed
Please enter the letters displayed:
(not case sensitive)